Human plasma derived hepatitis B vaccine: Kenyan experience.
To determine the efficacy and safety of hepaccine B. Vaccination on first-come-first-served basis. Kenya Medical Research Institute (KEMRI) staff and families at Nairobi, Kenya. A total of 107 vaccinees aged 0-10 years and 10 years and above. Antibody to hepatitis B surface antigen (anti HBs) checked one month after the third dose of the vaccine. Ninety seven per cent of the vaccinees developed antiHBs. Side effects were few in the form of soreness at site of injection and headache. Hepaccine B produced good immune response in vaccinees with minimal side effects.